دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Advancing President Biden’s Equity Agenda — Lessons from Disparities Work
Neil K. Aggarwal, M.D.
doi : 10.1056/NEJMp2101439
N Engl J Med 2021; 384:1481-1483
An Uncertain Public — Encouraging Acceptance of Covid-19 Vaccines
Gillian K. SteelFisher, Ph.D., Robert J. Blendon, Sc.D., and Hannah Caporello, B.A.
doi : 10.1056/NEJMp2100351
N Engl J Med 2021; 384:1483-1487
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19
The REMAP-CAP Investigators*
doi : 10.1056/NEJMoa2100433
N Engl J Med 2021; 384:1491-1502
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
Ivan O. Rosas, M.D., Norbert Br?u, M.D., Michael Waters, M.D., Ronaldo C. Go, M.D., Bradley D. Hunter, M.D., Sanjay Bhagani, M.D., Daniel Skiest, M.D., Mariam S. Aziz, M.D., Nichola Cooper, M.D., Ivor S. Douglas, M.D., Sinisa Savic, Ph.D., Taryn Youngstein, M.D., Lorenzo Del Sorbo, M.D., Antonio Cubillo Gracian, M.D., David J. De La Zerda, M.D., Andrew Ustianowski, Ph.D., Min Bao, M.D., Sophie Dimonaco, M.Sc., Emily Graham, Ph.D., Balpreet Matharu, M.D., Helen Spotswood, Ph.D., Larry Tsai, M.D., and Atul Malhotra, M.D.
doi : 10.1056/NEJMoa2028700
N Engl J Med 2021; 384:1503-1516
Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials.
A Microbiota-Directed Food Intervention for Undernourished Children
Robert Y. Chen, B.S., Ishita Mostafa, B.D.S., M.P.H., Matthew C. Hibberd, Ph.D., Subhasish Das, M.B., B.S., M.P.H., Mustafa Mahfuz, M.B., B.S., M.P.H., Nurun N. Naila, M.B., B.S., M.P.H., M. Munirul Islam, M.B., B.S., Ph.D., Sayeeda Huq, M.B., B.S., M.P.H., M. Ashraful Alam, M.P.H., Mahabub U. Zaman, M.P.H., Arjun S. Raman, M.D., Ph.D., Daniel Webber, M.D., Ph.D., Cyrus Zhou, B.S., Vinaik Sundaresan, B.S., Kazi Ahsan, M.B., B.S., M.P.H., Martin F. Meier, B.S., Michael J. Barratt, Ph.D., Tahmeed Ahmed, M.B., B.S., Ph.D., and Jeffrey I. Gordon, M.D.
doi : 10.1056/NEJMoa2023294
N Engl J Med 2021; 384:1517-1528
More than 30 million children worldwide have moderate acute malnutrition. Current treatments have limited effectiveness, and much remains unknown about the pathogenesis of this condition. Children with moderate acute malnutrition have perturbed development of their gut microbiota.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia, M.D., Sara A. Hurvitz, M.D., Sara M. Tolaney, M.D., M.P.H., Delphine Loirat, M.D., Ph.D., Kevin Punie, M.D., Mafalda Oliveira, M.D., Ph.D., Adam Brufsky, M.D., Ph.D., Sagar D. Sardesai, M.D., Kevin Kalinsky, M.D., Amelia B. Zelnak, M.D., Robert Weaver, M.D., Tiffany Traina, M.D., Florence Dalenc, M.D., Philippe Aftimos, M.D., Filipa Lynce, M.D., Sami Diab, M.D., Javier Cortés, M.D., Ph.D., Joyce O’Shaughnessy, M.D., Véronique Diéras, M.D., Cristiano Ferrario, M.D., Peter Schmid, M.D., Ph.D., Lisa A. Carey, M.D., Luca Gianni, M.D., Martine J. Piccart, M.D., Ph.D., Sibylle Loibl, M.D., Ph.D., David M. Goldenberg, Sc.D., M.D., Quan Hong, Ph.D., Martin S. Olivo, M.D., Loretta M. Itri, M.D., and Hope S. Rugo, M.D. for the ASCENT Clinical Trial Investigators*
doi : 10.1056/NEJMoa2028485
N Engl J Med 2021; 384:1529-1541
Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.
Adrenal Incidentaloma
Electron Kebebew, M.D.
doi : 10.1056/NEJMcp2031112
N Engl J Med 2021; 384:1542-1551
Orf
Cecil S. Qiu, M.D., and Arianna F. Yanes, M.D.
doi : 10.1056/NEJMicm2029641
N Engl J Med 2021; 384:1552
Striae and an Adrenal Mass
Jennifer H. Yo, M.B., B.S., and Shital Gandhi, M.D.
doi : 10.1056/NEJMicm2024730
N Engl J Med 2021; 384:e57
Case 12-2021: A 78-Year-Old Man with a Rash on the Scalp and Face
Michael K. Yoon, M.D., Hillary R. Kelly, M.D., Suzanne K. Freitag, M.D., Alexander G. Marneros, M.D., Ph.D., Miriam B. Barshak, M.D., and Diane G. Brackett, M.D.
doi : 10.1056/NEJMcpc2100276
N Engl J Med 2021; 384:1553-1562
Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
Eric J. Rubin, M.D., Ph.D., Dan L. Longo, M.D., and Lindsey R. Baden, M.D.
doi : 10.1056/NEJMe2103108
N Engl J Med 2021; 384:1564-1565
Microbial Nourishment for Undernutrition
Wendy S. Garrett, M.D., Ph.D.
doi : 10.1056/NEJMe2104212
N Engl J Med 2021; 384:1566-1567
Audio Interview: Covid-19 Vaccines and Pregnancy — A Conversation with CDC Director Rochelle Walensky
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., Rochelle P. Walensky, M.D., M.P.H., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2106836
N Engl J Med 2021; 384:e73
Preparing for the Future — Nanobodies for Covid-19?
Ram Sasisekharan, Ph.D.
doi : 10.1056/NEJMcibr2101205
N Engl J Med 2021; 384:1568-1571
Platform Trials — Beware the Noncomparable Control Group
doi : 10.1056/NEJMc2102446
N Engl J Med 2021; 384:1572-1573
Disposable E-Cigarette Use among U.S. Youth — An Emerging Public Health Challenge
doi : 10.1056/NEJMc2033943
N Engl J Med 2021; 384:1573-1576
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
doi : 10.1056/NEJMc2036242
N Engl J Med 2021; 384:1576-1578
Antenatal Dexamethasone for Early Preterm Birth in Low-Resource Countries
doi : 10.1056/NEJMc2102042
N Engl J Med 2021; 384:e58
